Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
People with the autoimmune disease scleroderma are vulnerable in COVID-19 due to frailty, lung involvement, and immunosuppression; they are representative of vulnerable groups in terms of COVID-19 mental health ramifications. No previous randomized controlled trials have tested mental health interventions during infectious disease outbreaks. We leveraged our existing ongoing cohort of over 2,000 people with scleroderma and existing partnerships to launch a new cohort, the Scleroderma Patient-centered Intervention Network (SPIN)-COVID- 19 Cohort. We enrolled over 800 people in the cohort to assess mental health during COVID-19. The SPIN-CHAT trial is embedded in the cohort and will test a 4-week (3x/week) videoconference intervention that provides social support and positive mental health education. The primary outcome is anxiety symptoms. SPIN-CHAT is being tested among people with scleroderma, but could be used with any population of vulnerable individuals who are isolated and experiencing high levels of anxiety in COVID-19, such as people with pre-existing medical conditions or older persons.
Brett Thombs;Andrea Benedetti
Zelalem Firisa Negeri
Scleroderma Canada
Epidemiology / Public health and policy
Other services (except public administration)
McGill University
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.